Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Operating Expenses: 2010-2025

Historic Operating Expenses for Iovance Biotherapeutics (IOVA) over the last 9 years, with Sep 2025 value amounting to $162.4 million.

  • Iovance Biotherapeutics' Operating Expenses rose 9.98% to $162.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $666.9 million, marking a year-over-year increase of 28.05%. This contributed to the annual value of $559.3 million for FY2024, which is 21.14% up from last year.
  • According to the latest figures from Q3 2025, Iovance Biotherapeutics' Operating Expenses is $162.4 million, which was down 6.54% from $173.7 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Operating Expenses registered a high of $173.7 million during Q2 2025, and its lowest value of $110.3 million during Q2 2023.
  • Its 3-year average for Operating Expenses is $138.9 million, with a median of $133.0 million in 2024.
  • Data for Iovance Biotherapeutics' Operating Expenses shows a peak YoY soared of 44.00% (in 2025) over the last 5 years.
  • Iovance Biotherapeutics' Operating Expenses (Quarterly) stood at $121.7 million in 2023, then spiked by 31.65% to $160.3 million in 2024, then rose by 9.98% to $162.4 million in 2025.
  • Its last three reported values are $162.4 million in Q3 2025, $173.7 million for Q2 2025, and $170.5 million during Q1 2025.